Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunology

Set Alert for Immunology

Pfizer Takes First Small Step Into Longevity Field With Gero Collaboration

Interest in longevity and anti-aging is gathering momentum, and Pfizer has dipped its toe in the water with an early-stage drug discovery partnership.

Deals Companies

Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work

After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.

Commercial Leadership

Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout

The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj

Clinical Trials Inflammation

Abionyx Looks To Next Steps As Renal Sepsis Candidate Succeeds At Phase IIa

The French firm’s lead asset has impressed in a Phase IIa trial in sepsis patients at risk of kidney injury, triggering discussions with regulators for a path forward in the challenging and life-threatening condition.

Clinical Trials Companies

SFA Therapeutics Harnesses Power Of Bacterial Metabolites To Treat Inflammatory Disease

Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.

Emerging Company Profile Companies

Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact

The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.

Sales & Earnings Business Strategies

Vera’s Atacicept Passes Phase II IgAN Trial But Data Pale Beside Chinook’s Pipeline Rival

The US biotech’s dual cytokine inhibitor has hit significance in a mid-stage trial with plans underway for a Phase III study, but concerns about its lacklustre efficacy when compared with a rival candidate from Chinook have taken the wind out of its sails.

Clinical Trials Renal

EVOQ Partners With Gilead On NanoDisc Approach To RA, Lupus

Michigan biotech follows 2021 collaboration in autoimmune disease with Amgen with its second tie-up, teaming up with Gilead in rheumatoid arthritis and systemic lupus erythematosus.

Deals Business Strategies

ICER: Antibodies For MS – Including TG’s – Need Big Price Cut For Cost-Effectiveness

The pricing watchdog said it found “insufficient evidence” to differentiate the benefit of TG’s ublituximab from other antibodies already on the market for multiple sclerosis.

Pricing Debate Inflammation

Sanofi To Advance Kymera’s IRAK4 Protein Degrader After Phase I Success

The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.

Inflammation Companies

Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor

Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.

M & A Business Strategies

UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success

Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.

Inflammation Clinical Trials
See All
UsernamePublicRestriction

Register